Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262,813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.
Luo Y, Gao Y, Niu Z, Zhang J, Liu Z, Zhang Y, Shen S, Jiang Y, Xiao M, Zhu Q. Luo Y, et al. Among authors: zhang j, zhang y. Quant Imaging Med Surg. 2024 May 1;14(5):3519-3533. doi: 10.21037/qims-23-1620. Epub 2024 Apr 26. Quant Imaging Med Surg. 2024. PMID: 38720854 Free PMC article.
Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients.
Pan B, Xu Y, Yao R, Cao X, Zhou X, Hao Z, Zhang Y, Wang C, Shen S, Luo Y, Zhu Q, Ren X, Kong L, Zhou Y, Sun Q. Pan B, et al. Among authors: zhang y. J Transl Med. 2023 Nov 9;21(1):798. doi: 10.1186/s12967-023-04523-7. J Transl Med. 2023. PMID: 37946210 Free PMC article.
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
Xu QQ, Pan B, Wang CJ, Zhou YD, Mao F, Lin Y, Guan JH, Shen SJ, Zhang XH, Xu YL, Zhong Y, Wang XJ, Zhang YN, Sun Q. Xu QQ, et al. Among authors: zhang yn, zhang xh. Oncotarget. 2016 Sep 27;7(39):63571-63582. doi: 10.18632/oncotarget.11541. Oncotarget. 2016. PMID: 27566580 Free PMC article. Review.
Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C, Zhou Y, Lin Y, Mao F, Guan J, Zhang X, Shen S, Wang X, Zhang Y, Pan B, Zhong Y, Peng L, Cao X, Yao R, Zhou X, Xu C, Xu Y, Sun Q. Wang C, et al. Among authors: zhang x, zhang y. BMC Cancer. 2022 Mar 14;22(1):269. doi: 10.1186/s12885-022-09346-1. BMC Cancer. 2022. PMID: 35287613 Free PMC article.
262,813 results
You have reached the last available page of results. Please see the User Guide for more information.